atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in one-on-one investor meetings at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021.
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
July 7, 2021
Articles
7:47 pm
JOIN THE ATAI #INSIGHTNETWORK
Receive the latest news on atai and innovations in the space.
Email